Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
This article was originally published in PharmAsia News
Executive Summary
Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.